A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
about
Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.Current status and future prospects of peptide-based cancer vaccines.Vaccination Expectations in HNSCC.[Human papillomavirus and squamous cell cancer of the head and neck region : Prognostic, therapeutic and prophylactic implications].Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.
P2860
A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
A phase 1/2a study to test the ...... llomavirus-associated cancers.
@en
type
label
A phase 1/2a study to test the ...... llomavirus-associated cancers.
@en
prefLabel
A phase 1/2a study to test the ...... llomavirus-associated cancers.
@en
P2093
P2860
P356
P1433
P1476
A phase 1/2a study to test the ...... llomavirus-associated cancers.
@en
P2093
Achim Schneider
Andreas M Kaufmann
Claudia Pauligk
Elena-Sophie Prigge
Elke Jäger
Julia Karbach
Madeleine Sauer
Magnus von Knebel Doeberitz
Matthias Kloor
Miriam Reuschenbach
P2860
P304
P356
10.1002/CNCR.29925
P407
P577
2016-03-07T00:00:00Z